Anti-neoplastic Agents Targeting T-cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and hyperproliferative disorders, particularly those involving T-cell, B-cell, and NK-cell proliferation, lack effective compounds with high activity, leading to inadequate therapeutic options for various lymphomas and leukemias.
Innovation Solution
Development of specific compounds, such as those described in Formulas I, II, III, and V, and their pharmaceutically acceptable salts, prodrugs, and isotopic variants, which are highly active against T-cell and B-cell proliferation, usable alone or in combination with other therapies like immunotherapy or bispecific T-cell Engagers, to treat cancers and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancers and hyperproliferative disorders are used, then existing therapeutic options are available, but they lack effective compounds with high activity against T-cell, B-cell, and NK-cell proliferation
Solution Approach 1:
The patent develops compounds with specific molecular structures (Formulas I, II, III, and V) that are optimized to target particular cell types (T-cells, B-cells, NK-cells) rather than having broad, non-specific activity. This local quality approach creates therapeutics with high activity against specific lymphoid neoplasms while maintaining selectivity
Solution Approach 2:
The invention modifies chemical parameters of the compound structures, including specific substitutions at defined positions in the molecular formulas, to enhance anti-proliferative activity. By systematically varying structural parameters and testing against different cell lines, the patent identifies compounds with optimized potency against specific cancer types
2Reliability
If highly specific compounds are developed for targeted cancers, then therapeutic efficacy improves, but the complexity of drug development and testing increases
Solution Approach 1:
The patent describes a series of compounds with a core structural framework (Formulas I, II, III, V) that can be systematically modified with different substituents to target multiple types of lymphoid neoplasms. This universal framework approach allows a single base structure to serve multiple therapeutic purposes across different cancer types, reducing overall development complexity
Solution Approach 2:
The invention divides the drug development process into systematic stages: defining core molecular frameworks, identifying variable substituent positions, screening against multiple cell lines, and optimizing specific compounds for particular indications. This segmentation of the development process makes the complex task of creating highly specific therapeutics more manageable and systematic
Data Source
AI summary
This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.